BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33813113)

  • 1. 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study'-author's reply.
    Lecomte R; Deschanvres C; Coudol S; Wargny M; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Aug; 27(8):1180-1181. PubMed ID: 33813113
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al.
    Buis DTP
    Clin Microbiol Infect; 2021 Aug; 27(8):1179. PubMed ID: 33581355
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
    Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefazolin versus cloxacillin in methicillin-susceptible Staphylococcus aureus endocarditis: Too good to be true? Authors' reply.
    Herrera-Hidalgo L; de Alarcón A
    Int J Infect Dis; 2024 May; 142():106979. PubMed ID: 38401779
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
    Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
    Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive Clavulanic Acid Abolishes the Cefazolin Inoculum Effect in an Experimental Rat Model of Methicillin-Sensitive Staphylococcus aureus Endocarditis.
    Miller WR; Singh KV; Arias CA; Murray BE
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
    Lefèvre B; Hoen B; Goehringer F; Sime WN; Aissa N; Alauzet C; Jeanmaire E; Hénard S; Filippetti L; Selton-Suty C; Agrinier N;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2605-2616. PubMed ID: 34383175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J; Echevarria KL; Traugott KA
    Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of a cefazolin inoculum effect associated with blaZ gene types, and clinical outcomes among methicillin-susceptible Staphylococcus aureus blood isolates of patients with infective endocarditis.
    Bourreau A; Le Mabecque V; Broquet A; Caillon J
    Infect Dis Now; 2023 Feb; 53(1):104626. PubMed ID: 36184048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
    Weis S; Kesselmeier M; Davis JS; Morris AM; Lee S; Scherag A; Hagel S; Pletz MW
    Clin Microbiol Infect; 2019 Jul; 25(7):818-827. PubMed ID: 30928559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis.
    Lee BJ; Wang SK; Constantino-Corpuz JK; Apolinario K; Nadler B; McDanel JS; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2019 Mar; 53(3):225-233. PubMed ID: 30476572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
    Lodise TP; McKinnon PS; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin.
    Carrizosa J; Santoro J; Kaye D
    Antimicrob Agents Chemother; 1978 Jan; 13(1):74-7. PubMed ID: 626493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Ulloa ER; Singh KV; Geriak M; Haddad F; Murray BE; Nizet V; Sakoulas G
    Clin Infect Dis; 2020 Sep; 71(6):1413-1418. PubMed ID: 31773134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
    Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX
    Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
    Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage.
    Vareil MO; Barret A; Vinclair C; Guerpillon B; Leyssene D; Jaouen AC; Alleman L; Wille H
    Infect Dis Now; 2021 May; 51(3):304-307. PubMed ID: 33934810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue.
    Nannini EC; Singh KV; Murray BE
    Clin Infect Dis; 2003 Nov; 37(9):1194-8. PubMed ID: 14557964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits.
    Carrizosa J; Kobasa WD; Kaye D
    Antimicrob Agents Chemother; 1980 Oct; 18(4):562-5. PubMed ID: 7447418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for methicillin-resistant Staphylococcus aureus.
    Torres-Tortosa M; Caballero-Granado FJ; Canueto J
    N Engl J Med; 2006 Nov; 355(20):2153-4; author reply 2155. PubMed ID: 17120350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.